The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 26, 2021
Filed:
Aug. 18, 2016
Applicant:
Children's Research Institute, Children's National Medical Center, Washington, DC (US);
Assignee:
Children's Research Institute, Children's National Medical Center, Washington, DC (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 38/16 (2006.01); A61P 37/06 (2006.01); A61P 35/02 (2006.01); A61K 31/7105 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 31/7105 (2013.01); A61K 38/08 (2013.01); A61K 38/164 (2013.01); A61K 38/1709 (2013.01); A61K 48/005 (2013.01); A61P 35/02 (2018.01); A61P 37/06 (2018.01); A61K 2300/00 (2013.01);
Abstract
A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject.